ClinicaliQ Trial Snapshot
- Nailfold Capillaroscopy in PH — Recruiting • Cardiology / Cardiovascular • NCT07768644.
- What is being tested: Nailfold capillaroscopy (microscopic examination of blood vessels in the nail fold) as a non-invasive diagnostic tool to identify pulmonary hypertension and distinguish it from other conditions causing similar symptoms.
- Patient eligibility overview: Adults presenting with suspected pulmonary hypertension or symptoms suggestive of connective tissue diseases (such as systemic sclerosis) that are associated with PH; patients must be able to consent and undergo capillaroscopy imaging.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal. Diagnosing PH currently involves a number of scans, breathing tests and often an invasive test called right heart catheterisation [RHC] (which involves inserting a tube into a large vein to measure the lung blood pressure from the). The investigators propose using a scan of the nailbeds called "Nailfold (Video) Capillaroscopy" to…
Eligibility Snapshot
- : For inpatient enrolment: * Suspected diagnosis of group 1,3 or 4 pulmonary hypertension undergoing inpatient assessment at nationally designated centre * Age > 18 years For follow up scanning of those enrolled as an inpatient: * Confirmed diagnosis of pulmonary hypertension assessed at nationally designated centre fulfilling criteria for group 1, 3 or 4 disease * Commencing PH targeted therapy, specifically one or more of: a phosphodiesterase 5 inhibitor (PDE5i), an ET receptor antagonist (ERA), parenteral prostanoid therapy, selexipag, riociguat, sotatercept. For outpatient enrolment * Confirmed diagnosis of pulmonary hypertension assessed at nationally designated centre fulfilling criteria for group 1, 3 or 4 disease * Age > 18 years * Escalating PH targeted therapy, specifically one or more of: a phosphodiesterase 5 inhibitor (PDE5i), an ET receptor antagonist (ERA), parenteral prostanoid therapy, selexipag, riociguat, sotatercept. Target of > 25% of patients recruited at diagnosis and to have an SSc-spectrum disorder fulfilling either ACR/EULAR 2013 or VEDOSS (very early diagnosis of SSc) criteria. Target of > 25% of patients recruited at diagnosis and to have non-SSc group 1 (PAH) diagnosis (as determined by national MDT decision).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.